Envision Healthcare Holdings Inc
MEDNAX Revenue and Income Rose After 3Q15 Results
MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.
Why Envision Healthcare Stock Rose ~2.4% Last Week
Healthcare service provider Envision Healthcare (EVHC) announced its agreement to be acquired by KKR (KKR) last week.
Envision Healthcare to Be Acquired by KKR
On June 11, Envision entered into a definitive acquisition agreement with KKR.
Mattel: S&P 500’s Top Gainer on April 11
Mattel, which is an American multinational toy manufacturing company, was the S&P 500’s top gainer on Wednesday.
UnitedHealth Group Drops Out of the Bid to Acquire Envision
On March 14, 2018, it was reported that UnitedHealth Group is no longer interested in acquiring Envision Healthcare
What Analysts Recommend for Universal Health Services
Of the 18 analysts covering Universal Health Services in February 2018, five analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating.
Analysts’ Ratings for Genesis Healthcare and Peers in February
Of the five analysts covering Genesis Healthcare in February 2018, one has given the stock a “buy” rating.
Key Risks Facing Mednax in 2017
Mednax (MD) bills payors for services provided to patients. These payors consist of government programs like Medicare and Medicaid, contracted managed care, third parties, and private pay patients.
Understanding Mednax’s Financial Position
In 3Q17, hurricanes negatively affected Mednax’s (MD) revenues by close to $2 million. According to the company, acquisitions in radiology, anesthesia, and neonatology contributed around 430 basis points to revenue growth.
A Closer Look at Mednax’s Business Strategy
Mednax (MD) has a proven track record of expertise in the administration of physician services and a methodical approach to clinical data warehousing in fields such as research, education, and quality.
The Latest Wall Street Recommendations for Mednax
Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating.
The Amsurg-Envision Material Adverse Effect Clause: Part 2
In this part of the series, we’ll look at the MAE clause of the Amsurg (AMSG) merger agreement with Envision Healthcare (EVHC) and how Amsurg could back out of the deal.